S

    Summit Therapeutics PLC (SMMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.62
    -0.11 (-0.80%)

    Market Cap: $10.95B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    47%(16/34)
    Avg Surprise
    -509.63%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.22
    Range$-0.31 - $-0.14
    12 analysts
    EPS Revisions
    2
    0
    7d
    2
    7
    30d
    EPS Estimate Drift
    90d ago$-0.21+1.0%
    60d ago$-0.22-1.5%
    30d ago$-0.22-1.5%
    7d ago$-0.22-0.0%
    Current$-0.22
    Revenue Consensus
    $53640
    Range$0 - $376000
    14 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.23
    Range$-0.62 - $0.04
    11 analysts
    Revenue Consensus
    $3M
    Range$-94490 - $11M
    15 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.23---
    Sep 26EST
    		-$-0.22---
    Jun 26
    Reported Jul 23
    		$-0.28$-0.26-7.69%Miss-133.3%
    Mar 26
    Reported Apr 30
    		$-0.18$-0.12-45.19%Miss-161.0%
    Dec 25
    Reported Feb 23
    		$-0.21$-0.01-2000.00%Miss-250.0%
    Sep 25
    Reported Oct 20
    		$-0.23$-0.04-475.00%Miss-283.3%
    Jun 25
    Reported Aug 11
    		$-0.12$-0.09-33.33%Miss-71.4%
    Mar 25
    Reported May 1
    		$-0.07$-0.07+0.73%Beat-35.4%
    Dec 24
    Reported Feb 24
    		$-0.06$-0.06+0.00%Beat-50.0%
    Sep 24
    Reported Oct 30
    		$-0.06$-0.05-20.00%Miss-100.0%
    Jun 24
    Reported Aug 6
    		$-0.07$-0.05-40.00%Miss-250.0%
    Mar 24
    Reported May 1
    		$-0.05$-0.05+0.00%Beat+96.5%
    Dec 23
    Reported Feb 20
    		$-0.04$-0.05+20.00%Beat+42.9%
    Sep 23
    Reported Nov 7
    		$-0.03N/AN/ABeat+78.6%
    Jun 23
    Reported Aug 9
    		$-0.02N/AN/ABeat+88.2%
    Mar 23
    Reported May 11
    		$-1.43$-1.43+0.00%Beat-550.0%
    Dec 22
    Reported Mar 9
    		$-0.07$-0.07+0.00%Beat+75.0%
    Sep 22
    Reported Nov 9
    		$-0.14$-0.14+0.00%Beat+6.7%
    Jun 22
    Reported Aug 11
    		$-0.17$-0.17+0.00%Beat+10.5%
    Mar 22
    Reported May 11
    		$-0.22$-0.22+0.00%Beat+79.0%
    Dec 21
    Reported Mar 17
    		$-0.28$-0.28+0.00%Beat-115.4%
    Sep 21
    Reported Nov 15
    		$-0.15$-0.21+28.57%Beat+87.9%
    Jun 21
    Reported Aug 11
    		$-0.19$-0.13-46.15%Miss-5.6%
    Mar 21
    Reported May 17
    		$-1.05$-0.21-400.00%Miss-3400.0%
    Dec 20
    Reported Mar 17
    		$-0.13$-0.16+18.75%Beat+40.9%
    Sep 20
    Reported Nov 16
    		$-1.24$-0.01-12300.00%Miss-520.0%
    Jun 20
    Reported Sep 29
    		$-0.18$-0.06-200.00%Miss+48.6%
    Mar 20
    Reported Jun 2
    		$-0.03$-0.03+0.00%Beat+94.0%
    Sep 19
    Reported Dec 17
    		$-0.22$-0.40+45.00%Beat-112.0%
    Mar 19
    Reported Jun 12
    		$-0.20$-0.16-25.00%Miss+50.0%
    Dec 18
    Reported Mar 27
    		$-0.35$-0.24-45.83%Miss-133.3%
    Sep 18
    Reported Dec 11
    		$-0.50$-0.12-316.67%Miss-158.8%
    Jun 18
    Reported Sep 20
    		$1.83$-0.30+710.00%Beat+557.5%
    Mar 18
    Reported Apr 13
    		$-0.40$-0.10-300.00%Miss+19.4%
    Sep 17
    Reported Dec 6
    		$-0.15$-0.10-50.00%Miss+62.5%
    Jun 17
    Reported Aug 31
    		$0.85$0.25+240.00%Beat-
    Mar 17
    Reported Jun 14
    		$-0.40$-0.14-185.71%Miss-
    Dec 16
    Reported Mar 29
    		$-0.50N/AN/ABeat-
    Sep 16
    Reported Dec 15
    		$-0.40$-0.02-1900.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio-13.27EV/EBITDA-5.32x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-192.50%ROIC-136.94%
    Financial Health
    Debt/Equity0.01xInterest CoverageN/A
    Current Ratio6.96xQuick Ratio6.96x
    Trading Statistics
    Beta-1.24Avg Volume5.42M
    52-Week High$29.2352-Week Low$12.07

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.35
    SMA 20$13.68
    SMA 50$14.09
    SMA 200$16.45
    EMA 10$13.61
    EMA 20$13.64
    EMA 50$14.20
    EMA 200$16.53

    MACD

    Line: -0.12Signal: -0.22Hist: 0.10

    ADX

    ADX: 13.7+DI: 27.2-DI: 27.2

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down60.0
    PSAR$15.08

    Bollinger Bands

    Upper Band$15.22
    Lower Band$12.14
    %B Position2253%(Upper)
    Band Width0.48

    RSI (14-Day)

    Neutral
    49.0

    Momentum Oscillators

    Stoch %K49.5
    Stoch %D52.1
    Williams %R-57.9
    ROC (10d)6.6%
    Momentum0.84
    CCI (20d)-11.1
    MFI (14d)43.7

    Volatility Measures

    ATR (14d)$0.87(6.4%)
    StdDev (20d)0.77
    Hist Vol67.3%(High)

    Volume Flow

    VWAP$13.60
    OBV-9.9M
    AD Line-70.0M
    CMF (20d)-0.106

    Volume Metrics

    Avg Vol (20d)5.5M
    Vol Ratio1.0x
    VWMA (20d)$13.60

    Pivot Points

    R3$14.98
    R2$14.61
    R1$14.17
    Pivot Point$13.80
    S1$13.36
    S2$12.99
    S3$12.55

    Advanced Oscillators

    TSI-3.80
    Ultimate Osc50.1
    KST-43.45

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$-235,000$0
    Cost of RevenueN/A$44,000$4,355N/A$37,000$25,000$14.94M$19,999$20,000$27,000$605,000$599,000
    Gross ProfitN/A$-44,000$-4,355N/A$-37,000$-25,000$-14,940,000$-19,999$-20,000$-27,000$-840,000$-599,000
    Operating Expenses$220.50M$195.21M$224.88M$234.21M$234.21M$51.75M$52.41M$43.66M$47.16M$33.59M$28.40M$16.80M
    R&D$157.73M$132.62M$147.29M$131.10M$131.10M$39.68M$41.04M$28.22M$36.23M$24.47M$19.46M$12.56M
    SG&A$62.76M$62.59M$77.58M$103.11M$103.11M$12.06M$11.53M$15.25M$10.93M$9.13M$9.08M$4.45M
    Operating Income$-220,496,000$-195,212,000$-224,875,000$-234,211,000$-234,211,000$-51,747,353$-52,408,526$-43,663,825$-47,161,220$-33,592,010$-28,404,210$-16,796,472
    Interest Income$0$0$0$0$0$0$0$0$0$0$2.38M$2.38M
    Interest Expense$0$0$0$0$0$0$9,000$2.46M$3.10M$3.12M$2.90M$2.72M
    Income Before Tax$-215,700,000$-189,424,000$-219,122,000$-231,793,000$-231,793,000$-48,699,065$-48,885,284$-42,075,179$-47,768,761$-34,451,048$-28,684,251$-17,432,528
    Income Tax Expense$0$0$0$0$0$0$24,000$264,000$-159,000$3.12M$-199,000$-265,000
    Net Income$-215,700,000$-189,424,000$-219,172,000$-231,793,000$-231,793,000$-48,699,065$-48,885,284$-42,075,179$-47,768,761$-34,451,048$-28,684,251$-17,432,528
    EBITDA$-215,700,000$-189,380,000$-219,080,000N/A$-231,751,000$-48,679,714$-48,858,712$-39,605,220$-35,273,811$-31,308,652$-25,763,719$-14,684,299
    EBITN/A$-189,424,000$-219,122,000N/A$-231,793,000$-48,699,065$-48,876,284$-39,620,179$-35,289,632$-31,330,048$-25,787,251$-14,710,528
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SMMT

    News

    HARMONi-GI1 Marks a Major Milestone for Ivonescimab in BTC – Summit Therapeutics

    Summit Therapeutics announced that its investigational therapy, Ivonescimab, in combination with chemotherapy, demonstrated a statistically significant overall survival benefit compared to durvalumab plus chemotherapy in a Phase III trial (HARMONi-GI1) for first-line advanced Biliary Tract Cancer (BTC). This trial, conducted by Akeso in China, is the first known Phase III study in advanced BTC to show superiority over an anti-PD-(L)1 combination and represents the first Phase III Ivonescimab readout beyond NSCLC. Ivonescimab is currently approved only by China's NMPA.

    Oncodaily•8/26/26•
    Bullish

    Summit Therapeutics (SMMT) Gains from Positive Phase III Trial Results Amid High Price-to-Sales Valuation

    Summit Therapeutics (SMMT) recently announced positive topline results from its Phase III HARMONi-GI1 trial for an advanced biliary tract cancer treatment, which was conducted in collaboration with Akeso. Despite a high Price-to-Sales ratio and ongoing unprofitability, the market anticipates substantial future growth driven by its promising clinical pipeline. The company's GF Score is low at 30/100, but significant insider purchases indicate strong internal confidence.

    GuruFocus•8/25/26•
    Bullish

    Summit Therapeutics (NASDAQ:SMMT) Clinical Pathway Gains Fresh Attention

    Summit Therapeutics (NASDAQ:SMMT), a clinical-stage biotechnology company, is gaining renewed attention due to updates on its development pipeline and market activities. The company focuses on precision medicines, particularly its leading oncology candidate, ivonescimab, and also has a diversified research approach including infectious diseases. Its future direction is closely tied to clinical progress, regulatory developments, and expanding its research programs, such as evaluating ivonescimab across multiple cancer types.

    Kalkine Media•8/22/26•
    Bullish

    Summit Therapeutics (NASDAQ:SMMT) Given "Neutral" Rating at HC Wainwright

    HC Wainwright has reissued a "Neutral" rating for Summit Therapeutics (NASDAQ:SMMT), aligning with the analyst consensus of "Hold" and an average target price of $24.25. The company's shares are trading near their 52-week low at $12.63, and it reported a quarterly EPS of ($0.28), slightly below estimates. Notably, corporate insiders have significantly increased their holdings, purchasing 7.87 million shares valued at approximately $103.6 million in the last 90 days.

    MarketBeat•8/18/26•
    Somewhat-Bearish

    Summit Therapeutics (NASDAQ:SMMT) Hits New 1-Year Low - Here's Why

    Summit Therapeutics (NASDAQ:SMMT) shares recently hit a new 52-week low, trading at approximately $12.20, below both their 50-day and 200-day moving averages. This drop follows lowered analyst price targets, a consensus "Hold" rating, and the company narrowly missing quarterly earnings estimates with a loss of $0.28 per share. Despite the stock's decline, company insiders have shown strong confidence, purchasing 7.87 million shares worth about $103.6 million in the last quarter, bringing their collective ownership to 83.5%.

    MarketBeat•8/17/26•
    Somewhat-Bearish

    Frequently Asked Questions About SMMT

    Does SMMT pay dividends?
    Summit Therapeutics PLC (SMMT) does not currently pay a regular dividend.
    What is SMMT's market cap?
    Summit Therapeutics PLC (SMMT) has a market capitalization of $10.95B with a current stock price of $13.62.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In